Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime Cd8 T cells and protect mice against tumor challenge.

November 1, 2010
Authors: Edlich, et al.
B-MoGen Authors: Leah Hogdal
Publication: Vaccine. 48(49): 7764-7773.
Published Date: November 2010
Examines ability of “cross-priming” T cells through vaccination to elicit and maintain a response against tumor or viral antigens.
Alternatives in immunotherapy aim to stimulate the immune system to react against neoplastic cells. This study explores cross-priming T cells, in which vaccination of antigen-expressing dendritic cells (DCs) induces effective and maintained responses against viral or tumor antigens. The authors used neoplastic cells that over-expressed Her2 as a model, and found that induction of T cells responses via cross-priming induced a potent, preventive anti-tumor response.